Oncobiologics has no home ground advantage. There is no clearly defined path with the FDA, EMA or any other regulatory agency. And it’s battling against the largest biotech and pharma companies in the world as they work to extend their patent exclusivity. How can it survive and bring biosimilars to the market at 50% of the cost?
The company is raising $50 million, on top of some $43 million it's raised this year, according to regulatory filings.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
New Jersey biosimilar maker Oncobiologics just raised $31 million. It's developing biosimilars for 11 monoclonal antibody drugs that will soon go off-patent, such as Humira, Avastin and Herceptin.
Oncobiologics, a New Jersey-based biotherapeutics company which had its ceremonial opening Friday, announced two deals that are valued by the company at nearly $80 million. The agreements include a licensing deal with early-stage biotechnology start-up Parilis Biopharmaceuticals, an early-stage biotech company for an undisclosed biotherapeutic product. The second is with a big pharma company to […]